The more you know about Alpha1 deficiency and lung disease (emphysema), the more you’ll understand how important treatment can be.
Alpha1 circulates in your bloodstream and helps protect the elastic structures of your lungs from an enzyme that can attack normal body tissue. Without enough functional Alpha1, lung damage can develop, usually in people between 20 and 50 years of age.
Talk to your doctor if you have questions about family testing, living with Alpha1 deficiency, or augmentation therapy.
Know how GLASSIA works. Know what treatment experience works best for you.
The Alpha1 protein protects the lung tissue by blocking certain enzyme-caused damage. Such damage can lead to severe lung disease, such as emphysema.
Alpha1 augmentation is chronic maintenance therapy. So, GLASSIA is typically given once every week to increase levels of Alpha1 in your blood and lungs.
GLASSIA’s flexibility of administration lets you decide where you want to infuse. Talk to your healthcare provider about which administration option works best for you:
†If self-administration is deemed appropriate, ensure that you receive detailed instructions and adequate training on how to administer at home or other appropriate setting and have demonstrated the ability to independently administer GLASSIA.
Talk to your doctor about GLASSIA.
Know that OnePath is here for you after you and your physician choose your treatment path.
After you enroll in OnePath, you will receive a dedicated Patient Support Manager who will be your main point of contact throughout your treatment journey.‡ Your Patient Support Manager will work with you one-on-one to make sure you have access to your prescribed Takeda medication.
He or she will help you navigate many different aspects of your therapy, from insurance and financial options to training and prescription fulfillment.
The OnePath Co-Pay Assistance Program helps cover certain out-of-pocket treatment costs for eligible, commercially insured patients who are enrolled in OnePath.
The following are covered up to the program maximum and may be paid directly to the provider:
At a minimum, to be eligible for the program, a patient must:
‡OnePath is open to all patients taking GLASSIA for its indicated use and who complete the GLASSIA OnePath Start Form, which provides OnePath with your consent to provide product support.
§Subject to program terms, limits, and conditions
‖IMPORTANT NOTICE: The OnePath Copay Assistance Program (the Program) is not valid for prescriptions eligible to be reimbursed, in whole or in part, by Medicaid, Medicare (including Medicare Part D), Tricare, Medigap, VA, DoD, or other federal or state programs (including any medical or state prescription drug assistance programs). No claim for reimbursement of the out-of-pocket expense amount covered by the Program shall be submitted to any third party payer, whether public or private. The Program cannot be combined with any other rebate/coupon, free trial, or similar offer. Copayment assistance under the Program is not transferable. The Program only applies in the United States, including Puerto Rico and other U.S. territories, and does not apply where prohibited by law, taxed, or restricted. This does not constitute health insurance. Void where use is prohibited by your insurance provider. If your insurance situation changes you must notify the Program immediately at 1-866-888-0660. Coverage of certain administration charges will not apply for patients residing in states where it is prohibited by law. Takeda reserves the right to rescind, revoke, or amend the Program at any time without notice.
Call OnePath at 1-866-888-0660. OnePath is available Monday through Friday, 8:30 AM to 8:00 PM ET. Keep the OnePath number (1-866-888-0660) in your phone so you don’t confuse us with spam calls. If you miss a call from us, please call us back. If you give us permission, we can leave a voicemail saying why we called.Visit OnePath.com
Sign up, and we’ll make sure you get the latest information about Alpha1 deficiency and GLASSIA.
What is GLASSIA?
GLASSIA is a medicine containing human Alpha₁-Proteinase Inhibitor (Alpha₁-PI) also known as alpha₁-antitrypsin (AAT) and is used to treat adults with lung disease (emphysema) because of severe Alpha1 antitrypsin (AAT) deficiency. GLASSIA is not meant to be used as a therapy in individuals with lung disease other than severe Alpha₁-PI deficiency.
What is the most important information I need to know about GLASSIA?
Who should not use GLASSIA?
Do not use GLASSIA if you:
What are the possible or reasonably likely side effects of GLASSIA?
The most common side effects that may occur are headache and upper respiratory tract infections
Other possible side effects of GLASSIA include:
These are not all the possible side effects. Tell your HCP about any side effect that bothers you or that does not go away.
For additional safety information, click for Information For Patients including Instructions For Use and discuss with your HCP.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1‑800‑FDA‑1088.